# A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors

> **NCT05129280** · PHASE1 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 23 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** RO7444973
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT05129280
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-25
- **Primary completion:** 2023-07-12
- **Final completion:** 2023-07-12
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** The study was terminated due to program discontinuation.
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05129280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05129280, "A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05129280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*